Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuru Chen

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Theranostics|July 14, 2022
FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblastsYushen Wu, Ziying Yi, Jie Li, et al.
Nature Communications|May 21, 2026
Macrophage ALDH2 drives immunotherapy resistance by silencing CXCL9 through metabolic-epigenetic crosstalkHuiying Fang, Jiazheng Sun, Qian Xiao, et al.
The Journal of Clinical Investigation|November 15, 2024
Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapyDaqiang Song, Yushen Wu, Jie Li, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Theranostics|July 14, 2022
FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblastsYushen Wu, Ziying Yi, Jie Li, et al.
Nature Communications|May 21, 2026
Macrophage ALDH2 drives immunotherapy resistance by silencing CXCL9 through metabolic-epigenetic crosstalkHuiying Fang, Jiazheng Sun, Qian Xiao, et al.
The Journal of Clinical Investigation|November 15, 2024
Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapyDaqiang Song, Yushen Wu, Jie Li, et al.
Pageof 9